Market Place
Sourcing Support
MATEON’S UPDATE ON C001 - GLOBAL STUDY FOR OT-101 AGAINST COVID-19
08 Mar 2021 //
GLOBENEWSWIRE
MATEON’S GLOBAL STUDY FOR OT-101/ TGF-? INHIBITOR AGAINST COVID-19
30 Dec 2020 //
GLOBENEWSWIRE
FDA Granted Pediatric Disease Designation for OXi-4503
16 Sep 2020 //
GLOBENEWSWIRE
Mateon and Asili Research Alliance Enter Into Partnership for the Development
20 Jul 2020 //
BIOSPACE
Mateon Therapeutics to fund observational studies of Artemisinin
13 Jul 2020 //
GLOBENEWSWIRE
Company expands its management team to accelerate the devP of OT-101
09 Jul 2020 //
GLOBENEWSWIRE
Mateon is Selected by IBM Watson Health for the Use of IBM Ph II of OT-101
24 Jun 2020 //
GLOBENEWSWIRE
Mateon Announces Achievement of Milestone Under Licensing of OT-101/IL-2
10 Jun 2020 //
GLOBENEWSWIRE
Mateon Provides Update on its R&D Effort Against COVID-19
30 Apr 2020 //
BIOSPACE
Mateon Announces the Filing of an IND US FDA Evaluate its Antisense Drug OT-101
27 Apr 2020 //
BIOSPACE
MATEON EXPANDS ITS COVID-19 THERAPEUTIC PROGRAM TO INCLUDE ARTEMISININ
08 Apr 2020 //
MATEON
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.